📣 VC round data is live. Check it out!

Myomo Valuation Multiples

Discover revenue and EBITDA valuation multiples for Myomo and similar public comparables like Vivos, BrainCool, Q-linea, Spirit Scientific Co and more.

Myomo Overview

About Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).


Founded

2004

HQ

United States

Employees

185

Website

myomo.com

Financials (LTM)

Revenue: $42M
EBITDA: ($11M)

EV

$33M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Myomo Financials

Myomo reported last 12-month revenue of $42M and negative EBITDA of ($11M).

In the same LTM period, Myomo generated $28M in gross profit, ($11M) in EBITDA losses, and had net loss of ($15M).

Revenue (LTM)


Myomo P&L

In the most recent fiscal year, Myomo reported revenue of $41M and EBITDA of ($11M).

Myomo is unprofitable as of last fiscal year, with gross margin of 66%, EBITDA margin of (28%), and net margin of (38%).

See analyst estimates for Myomo
LTMLast FY202320242025202620272028
Revenue$42M$41M$19M$33M$41M
Gross Profit$28M$27M$13M$23M$27M
Gross Margin67%66%69%71%66%
EBITDA($11M)($11M)($8M)($5M)($13M)
EBITDA Margin(25%)(28%)(40%)(17%)(31%)
EBIT Margin(32%)(35%)(43%)(19%)(35%)
Net Profit($15M)($16M)($8M)($6M)($16M)
Net Margin(35%)(38%)(42%)(19%)(38%)

Financial data powered by Morningstar, Inc.

Myomo Stock Performance

Myomo has current market cap of $30M, and enterprise value of $33M.

Market Cap Evolution


Myomo's stock price is $0.78.

Myomo share price decreased by 9.5% in the last 30 days, and by 73.8% in the last year.

Myomo has an EPS (earnings per share) of $-0.40.

See more trading valuation data for Myomo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$33M$30M-8.4%-9.5%0.4%-73.8%$-0.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Myomo Valuation Multiples

Myomo trades at 0.8x EV/Revenue multiple, and (3.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Myomo

EV / Revenue (LTM)


Myomo Financial Valuation Multiples

As of May 13, 2026, Myomo has market cap of $30M and EV of $33M.

Myomo has a P/E ratio of (2.1x).

LTMLast FY202320242025202620272028
EV/Revenue0.8x0.8x1.7x1.0x0.8x
EV/EBITDA(3.1x)(2.9x)(4.3x)(6.1x)(2.6x)
EV/EBIT(2.5x)(2.3x)(4.0x)(5.4x)(2.3x)
EV/Gross Profit1.2x1.2x2.5x1.4x1.2x
P/E(2.1x)(1.9x)(3.7x)(4.9x)(1.9x)
EV/FCF(2.1x)(1.9x)(5.3x)(7.2x)(1.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Myomo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Myomo Margins & Growth Rates

Myomo grew revenue by 9% but EBITDA decreased by 18% in the last fiscal year.

In the most recent fiscal year, Myomo reported gross margin of 66%, EBITDA margin of (28%), and net margin of (38%).

See estimated margins and future growth rates for Myomo

Myomo Margins

Last FY202420252026202720282029
Gross Margin66%71%66%69%
EBITDA Margin(28%)(17%)(31%)(21%)
EBIT Margin(35%)(19%)(35%)(26%)
Net Margin(38%)(19%)(38%)(29%)
FCF Margin(44%)(14%)(44%)(28%)

Myomo Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%69%26%9%
Gross Profit Growth14%76%16%14%
EBITDA Growth(18%)(30%)133%(25%)
EBIT Growth(20%)(25%)132%(20%)
Net Profit Growth(17%)(24%)152%(17%)
FCF Growth(30%)(26%)284%(30%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Myomo Operational KPIs

Myomo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Myomo's Rule of 40 is (13%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Myomo's Rule of X is 0% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Myomo
LTMLast FY202320242025202620272028
Rule of 40(15%)(13%)
Bessemer Rule of X0%0%
Revenue per Employee$0.2M
Opex per Employee$0.2M
S&M Expenses to Revenue49%50%38%50%
G&A Expenses to Revenue34%34%38%34%
R&D Expenses to Revenue16%17%14%15%17%
Opex to Revenue101%111%90%101%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Myomo Competitors

Myomo competitors include Vivos, BrainCool, Q-linea, Spirit Scientific Co, Polyrizon, AnteoTech, CS Diagnostics, Genematrix, Finemedix and Genomtec.

Most Myomo public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vivos441.3x(9.5x)
BrainCool6.8x6.6x(8.1x)(9.3x)
Q-linea6.6x(0.5x)
Spirit Scientific Co2.3x11.0x
Polyrizon(5.3x)
AnteoTech40.1x43.3x(7.6x)(11.6x)
CS Diagnostics384.9x
Genematrix2.7x(24.6x)

This data is available for Pro users. Sign up to see all Myomo competitors and their valuation data.

Start Free Trial

Myomo Funding History

Before going public, Myomo raised $12M in total equity funding, across 2 rounds.


Myomo Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-15Series BMountain Group Capital$5M
Oct-13Series A$7MMyomo, a Cambridge, Massachusetts-based medical technology company, develops myoelectric-powered orthotic devices like the MyoPro custom orthosis to help patients with paralysis from stroke, traumatic brain injury, cerebral palsy, spinal cord injury, multiple sclerosis, or ALS regain arm function. In October 2013, Myomo closed a $7 million Series A funding round with participation from 33 investors, including new investor Mountain Group Capital and angel investors, finalizing with a $2 million tranche. Byron Smith from Mountain Group Capital joined the board of directors. The funds supported working capital to expand distribution of the MyoPro through orthotics and prosthetics facilities nationwide.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Myomo

When was Myomo founded?Myomo was founded in 2004.
Where is Myomo headquartered?Myomo is headquartered in United States.
How many employees does Myomo have?As of today, Myomo has over 185 employees.
Who is the CEO of Myomo?Myomo's CEO is Paul R. Gudonis.
Is Myomo publicly listed?Yes, Myomo is a public company listed on NYSE American.
What is the stock symbol of Myomo?Myomo trades under MYO ticker.
When did Myomo go public?Myomo went public in 2017.
Who are competitors of Myomo?Myomo main competitors include Vivos, BrainCool, Q-linea, Spirit Scientific Co, Polyrizon, AnteoTech, CS Diagnostics, Genematrix, Finemedix, Genomtec.
What is the current market cap of Myomo?Myomo's current market cap is $30M.
What is the current revenue of Myomo?Myomo's last 12 months revenue is $42M.
What is the current revenue growth of Myomo?Myomo revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Myomo?Current revenue multiple of Myomo is 0.8x.
Is Myomo profitable?No, Myomo is not profitable.
What is the current EBITDA of Myomo?Myomo has negative EBITDA and is not profitable.
What is Myomo's EBITDA margin?Myomo's last 12 months EBITDA margin is (25%).
What is the current EV/EBITDA multiple of Myomo?Current EBITDA multiple of Myomo is (3.1x).
What is the current FCF of Myomo?Myomo's last 12 months FCF is ($16M).
What is Myomo's FCF margin?Myomo's last 12 months FCF margin is (39%).
What is the current EV/FCF multiple of Myomo?Current FCF multiple of Myomo is (2.1x).
How many companies Myomo has acquired to date?Myomo hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Myomo has invested to date?Myomo hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Myomo

Lists including Myomo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial